HCEG Healthcare Ent.

RNS Number:2137R
Healthcare Enterprise Group PLC
14 February 2007

14 February 2007

Healthcare Enterprise Group PLC

EPA approval for Ebiox surface hygiene products



Healthcare Enterprise Group PLC ("HCEG" or "the Group", AIM: HCEG) is pleased to
announce that its wholly-owned subsidiary, Ebiox Limited, has secured U.S.
Environment Protection Agency ("EPA") approval for its patented concentrate and
spray disinfectants.



TruKleen, the registered trade name of the Ebiox surface hygiene products in the
U.S., offers significant advantages over other surface cleaners in the U.S.
market. By removing biofilm and cleaning to the molecular level, TruKleen is
effective against pathogens including viruses, fungi and bacteria such as MRSA.
TruKleen is free of damaging chemicals and skin irritants such as alcohols,
phenols, chlorine and aldehydes. It is therefore well suited for repeated use on
washable surfaces over protracted periods of time.



Applications for individual U.S. state approvals are being submitted immediately
and may take up to six months. These approvals will allow HCEG to distribute
TruKleen products in a wide range of markets.



Once individual state approvals are secured, HCEG will look to sign further
field of use agreements in the healthcare market and exploit additional
opportunities within broader markets such as agriculture, food processing and
facilities management.



HCEG recently announced a $4.5 million agreement over 5 years with Sultan
Healthcare Inc. ("Sultan") for the distribution of Ebiox products in the dental
market outside North America. As part of that agreement, the Group will now
commence discussions with Sultan to extend its exclusive distribution rights to
the dental market within North America with an associated additional financial
commitment.



Lyndon Gaborit, HCEG Executive Deputy Chairman commented:



"Regulatory approval in this world market is a major achievement for the Group.
The U.S. approval process for these products has taken longer than expected
owing to the unique make up of our products. This approval is a further
validation of our technology and products."



"TruKleen has huge potential in the U.S. as these non-alcohol surface hygiene
products have significant practical advantages whilst being more effective in
cleaning and decontaminating.



 "With a commitment from Sultan already endorsing Ebiox products in other
territories, we are confident that U.S. distribution contracts can be secured."



Enquiries:



Healthcare Enterprise Group                             + 44 (0)20 7351 7500
Lyndon Gaborit, Executive Deputy Chairman

College Hill                                            + 44 (0) 20 7457 2020
Adrian Duffield / Corinna Dorward



Notes



Healthcare Enterprise Group PLC



HCEG is a business engaged in medical product distribution, occupational health,
and first aid markets.  These businesses underpin a range of innovative medical
devices. HCEG is listed on the Alternative Investment Market ("AIM") of the
London Stock Exchange.

Ebiox

Patented decontamination and disinfectant products that are safe and alcohol
free, but substantially more effective than conventional methods at removing and
destroying embedded micro-organisms. The Ebiox range includes hand hygiene
products, surface disinfectants, products to clean and decontaminate surgical
instruments, and dental cleaning products. TruKleen is the U.S. equivalent of
Ebiox's Trionic surface hygiene range which is CE marked (Class 11a) for use in
the European Economic Area.

Sultan Healthcare, Inc.



Sultan, founded in 1872, is a leading manufacturer and distributor of Dental
Materials, Infection Control Products, Preventives and Oral Pharmaceuticals.
Sultan has three distribution centres: Englewood, New Jersey, USA; Ontario,
Canada and Amsterdam, The Netherlands, supporting sales through distribution
partners into 70 countries. Distribution partners are supported by territory
managers in each market worldwide, giving Sultan wide coverage in all dental
markets.



HCEG already has an agreement with Sultan for the exclusive marketing of the
Ebiox range of disinfection products to the dental sector in UK, continental
Europe, Latin America, South America, Asia and Africa. Sultan has also been
granted a non exclusive right to sell Ebiox into the medical supply market.  The
agreement which is for an initial term of five years, requires Sultan to
purchase a minimum US$4.5 million (#2.33 million) of Ebiox products over that
time, including US$625,000 (#325,000) in 2007, US$875,000 (#455,000) in 2008,
and US$1 million (#520,000) in each of the following three years. Sultan has
agreed to meet these minimum purchase levels as a contractual obligation,
subject only to Ebiox's capacity to supply.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

REAOKNKNOBKDFBD

Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Jul 2023 to Jul 2024